NO20041225L - Rekombinant anti-osteopontinantistoff og anvendelse derav - Google Patents
Rekombinant anti-osteopontinantistoff og anvendelse deravInfo
- Publication number
- NO20041225L NO20041225L NO20041225A NO20041225A NO20041225L NO 20041225 L NO20041225 L NO 20041225L NO 20041225 A NO20041225 A NO 20041225A NO 20041225 A NO20041225 A NO 20041225A NO 20041225 L NO20041225 L NO 20041225L
- Authority
- NO
- Norway
- Prior art keywords
- recombinant anti
- osteopontin antibody
- osteopontin
- antibody
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001290700 | 2001-09-25 | ||
PCT/JP2002/009868 WO2003027151A1 (fr) | 2001-09-25 | 2002-09-25 | Anticorps recombinant anti-osteopontine et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20041225L true NO20041225L (no) | 2004-05-25 |
Family
ID=19112969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041225A NO20041225L (no) | 2001-09-25 | 2004-03-23 | Rekombinant anti-osteopontinantistoff og anvendelse derav |
Country Status (16)
Country | Link |
---|---|
US (1) | US7241873B2 (fr) |
EP (1) | EP1431310A4 (fr) |
JP (1) | JPWO2003027151A1 (fr) |
KR (1) | KR20040048899A (fr) |
CN (1) | CN100352844C (fr) |
AU (1) | AU2002332290B2 (fr) |
BR (1) | BR0213078A (fr) |
CA (1) | CA2461529A1 (fr) |
HK (1) | HK1084127A1 (fr) |
HU (1) | HUP0402049A3 (fr) |
MX (1) | MXPA04002837A (fr) |
NO (1) | NO20041225L (fr) |
NZ (1) | NZ531818A (fr) |
PL (1) | PL369446A1 (fr) |
RU (1) | RU2305111C2 (fr) |
WO (1) | WO2003027151A1 (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040234524A1 (en) * | 2001-04-05 | 2004-11-25 | Toshimitsu Uede | Anti-osteopontin antibody and use thereof |
EP1431310A4 (fr) | 2001-09-25 | 2005-03-23 | Immuno Biological Lab Co Ltd | Anticorps recombinant anti-osteopontine et son utilisation |
AU2003258127A1 (en) * | 2002-08-06 | 2004-02-23 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
WO2004103403A1 (fr) * | 2003-05-23 | 2004-12-02 | Immuno-Biological Laboratories Co., Ltd. | Inhibiteur d'activation cellulaire immunocompetente et son utilisation |
WO2005047484A2 (fr) * | 2003-11-07 | 2005-05-26 | Ciphergen Biosystems, Inc. | Biomarqueurs pour la maladie d'alzheimer biomarkers for alzheimer's disease |
JP4495208B2 (ja) | 2004-02-27 | 2010-06-30 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ccpおよび血清アミロイドaの測定による慢性関節リウマチの評価方法 |
CA2552425C (fr) * | 2004-02-27 | 2018-02-06 | F. Hoffmann-La Roche Ag | Methode permettant d'evaluer la polyarthrite rhumatoide en mesurant le taux de facteur rhumatoide et d'interleukine 6 |
CA2589860A1 (fr) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
CA2607060A1 (fr) * | 2005-05-04 | 2006-11-09 | Australian Stem Cell Centre Limited | Selection, culture et creation de cellules souches hematopoietiques determinees pour une lignee |
MY185597A (en) * | 2005-09-20 | 2021-05-24 | Avantor Performance Mat Inc | Vegetarian protein a preparation and methods thereof |
BRPI0711229A2 (pt) * | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
JP5399710B2 (ja) * | 2006-10-26 | 2014-01-29 | 株式会社ジーンテクノサイエンス | 細胞外マトリックスタンパク質のアミノ酸配列rgdに対する抗体およびその製法と用途 |
CN101680887B (zh) * | 2007-03-30 | 2014-06-25 | 褚圣-贾斯汀公司 | 测定脊柱侧凸风险的方法 |
KR100894265B1 (ko) * | 2007-06-05 | 2009-04-21 | 재단법인서울대학교산학협력재단 | 골형성 촉진 펩타이드를 함유하는 주입형 골재생재 |
EP2170960B1 (fr) | 2007-07-13 | 2015-07-29 | Bac Ip B.V. | Protéines de liaison d'antigène à un seul domaine qui se lient à un igg de mammifère |
AU2008334976B2 (en) * | 2007-12-13 | 2013-05-23 | Monsanto Technology Llc | Compositions and methods for early pregnancy diagnosis |
EP2261254A3 (fr) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anticorps anti-amyloïdes et leurs utilisations |
PT2243829E (pt) * | 2008-01-11 | 2014-10-24 | Astellas Pharma Inc | Anticorpo anti-integrina-alfa9 humana humanizado melhorado |
KR101746861B1 (ko) * | 2008-04-24 | 2017-06-14 | 가부시키가이샤 진 테크노 사이언스 | 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도 |
KR20110014607A (ko) * | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
MX2010013239A (es) * | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
UY31861A (es) * | 2008-06-03 | 2010-01-05 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
MX2010014574A (es) * | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
US8372639B2 (en) | 2009-02-23 | 2013-02-12 | Gene Techno Science Co., Ltd. | Anti-human α9 integrin antibody and use thereof |
BRPI1012195A2 (pt) * | 2009-05-01 | 2018-04-24 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
IN2012DN01981A (fr) * | 2009-09-24 | 2015-07-24 | Gene Techno Science Co Ltd | |
RU2012119756A (ru) * | 2009-10-15 | 2013-11-20 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
US20120263722A1 (en) * | 2010-11-04 | 2012-10-18 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
JP2014523867A (ja) | 2011-05-27 | 2014-09-18 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 抗emr1抗体 |
MX2014008101A (es) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. |
TW201811825A (zh) | 2012-11-01 | 2018-04-01 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
UA121866C2 (uk) * | 2014-08-06 | 2020-08-10 | Астеллас Фарма Інк. | АНТИТІЛО ДО Ig<font face="Symbol">b </font>ЛЮДИНИ |
WO2016094881A2 (fr) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Protéines de liaison à lrp-8 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US10349259B2 (en) * | 2016-09-23 | 2019-07-09 | Apple Inc. | Broadcasting a device state in a wireless communication network |
CN114867746A (zh) * | 2019-08-09 | 2022-08-05 | 小利兰·斯坦福大学董事会 | 抗骨桥蛋白的治疗性抗体 |
CN115558015B (zh) * | 2022-10-12 | 2024-01-19 | 生工生物工程(上海)股份有限公司 | 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US171358A (en) * | 1875-12-21 | Improvement in machines for trimming and punching roofing-slates | ||
US239400A (en) * | 1881-03-29 | Tobacco-fork | ||
US125023A (en) * | 1872-03-26 | Improvement in sand dredging-machines | ||
US1408113A (en) * | 1921-01-28 | 1922-02-28 | Mason Richard Colbert | Well-measuring device |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE256751T1 (de) | 1993-03-11 | 2004-01-15 | Chemo Sero Therapeut Res Inst | Monoklonaler anti-hiv antikörper |
US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
EP0705842A2 (fr) | 1994-10-06 | 1996-04-10 | Hoechst Aktiengesellschaft | Régulation des gènes par stimulation du chondrocytes avec 1L-1bêta |
US6686444B2 (en) | 1996-08-22 | 2004-02-03 | Children's Medical Center Corporation | Osteopontin derived chemotactic peptides and methods of use |
WO1998008379A1 (fr) | 1996-08-27 | 1998-03-05 | Dana-Farber Cancer Institute | Procedes d'identification de modulateurs d'interactions cellulaires induites par l'osteopontine |
WO1998056405A1 (fr) | 1997-06-10 | 1998-12-17 | Whitehead Institute For Biomedical Research | Procede utilisant l'osteopontine pour moduler une reponse immunitaire |
JP2002500898A (ja) | 1997-08-15 | 2002-01-15 | チルドレンズ メディカル センター コーポレーション | オステオポンチン被膜表面及びその利用法 |
US6118044A (en) * | 1997-11-14 | 2000-09-12 | Sankyo Company, Limited | Transgenic animal allergy models and methods for their use |
US6414219B1 (en) | 1998-06-30 | 2002-07-02 | Rutgers, The State University Of New Jersey | Osteopontin knock-out mouse and methods of use thereof |
AU773350B2 (en) | 1999-04-15 | 2004-05-20 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
MXPA01010403A (es) | 1999-04-15 | 2004-09-10 | Childrens Medical Center | Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos. |
US7504232B2 (en) * | 2000-03-23 | 2009-03-17 | Smithkline Beecham Corporation | Method of screening for inhibitors of osteopontin |
AU2002213346B2 (en) | 2000-10-18 | 2006-05-11 | Children's Medical Center Corporation | Osteopontin-coated surfaces and methods of use |
US20040234524A1 (en) * | 2001-04-05 | 2004-11-25 | Toshimitsu Uede | Anti-osteopontin antibody and use thereof |
CA2454307A1 (fr) | 2001-07-19 | 2003-01-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anticorps de recepteur ige antihumain de type humain et fragment d'anticorps |
EP1431310A4 (fr) | 2001-09-25 | 2005-03-23 | Immuno Biological Lab Co Ltd | Anticorps recombinant anti-osteopontine et son utilisation |
WO2003046135A2 (fr) | 2001-11-21 | 2003-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et methodes associees a l'osteopontine |
CN103518888A (zh) * | 2013-10-14 | 2014-01-22 | 李民庆 | 一种养心宁神茶配方 |
-
2002
- 2002-09-25 EP EP02768058A patent/EP1431310A4/fr not_active Withdrawn
- 2002-09-25 BR BR0213078-5A patent/BR0213078A/pt not_active IP Right Cessation
- 2002-09-25 AU AU2002332290A patent/AU2002332290B2/en not_active Ceased
- 2002-09-25 RU RU2004112540/13A patent/RU2305111C2/ru not_active IP Right Cessation
- 2002-09-25 HU HU0402049A patent/HUP0402049A3/hu unknown
- 2002-09-25 CN CNB028234138A patent/CN100352844C/zh not_active Expired - Fee Related
- 2002-09-25 MX MXPA04002837A patent/MXPA04002837A/es not_active Application Discontinuation
- 2002-09-25 KR KR10-2004-7004266A patent/KR20040048899A/ko not_active Application Discontinuation
- 2002-09-25 NZ NZ531818A patent/NZ531818A/en unknown
- 2002-09-25 US US10/489,866 patent/US7241873B2/en not_active Expired - Fee Related
- 2002-09-25 JP JP2003530737A patent/JPWO2003027151A1/ja not_active Ceased
- 2002-09-25 CA CA002461529A patent/CA2461529A1/fr not_active Abandoned
- 2002-09-25 PL PL02369446A patent/PL369446A1/xx unknown
- 2002-09-25 WO PCT/JP2002/009868 patent/WO2003027151A1/fr not_active Application Discontinuation
-
2004
- 2004-03-23 NO NO20041225A patent/NO20041225L/no not_active Application Discontinuation
-
2006
- 2006-04-06 HK HK06104204A patent/HK1084127A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0213078A (pt) | 2004-11-23 |
RU2004112540A (ru) | 2005-04-20 |
HUP0402049A3 (en) | 2009-04-28 |
AU2002332290B2 (en) | 2007-11-08 |
US20060002923A1 (en) | 2006-01-05 |
MXPA04002837A (es) | 2005-11-04 |
EP1431310A4 (fr) | 2005-03-23 |
KR20040048899A (ko) | 2004-06-10 |
HK1084127A1 (en) | 2006-07-21 |
CN100352844C (zh) | 2007-12-05 |
EP1431310A1 (fr) | 2004-06-23 |
HUP0402049A2 (hu) | 2005-01-28 |
WO2003027151A1 (fr) | 2003-04-03 |
CA2461529A1 (fr) | 2003-04-03 |
NZ531818A (en) | 2005-10-28 |
JPWO2003027151A1 (ja) | 2005-01-06 |
US7241873B2 (en) | 2007-07-10 |
RU2305111C2 (ru) | 2007-08-27 |
CN1688604A (zh) | 2005-10-26 |
PL369446A1 (en) | 2005-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20041225L (no) | Rekombinant anti-osteopontinantistoff og anvendelse derav | |
CY2019022I1 (el) | Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους | |
DK1390389T3 (da) | Cripto-blokerende antistoffer og anvendelser deraf | |
NO20034405L (no) | Anti-ostepontin-antistoff og anvendelse derav | |
AU2002332290A1 (en) | Recombinant anti-osteopontin antibody and use thereof | |
HUP0400284A3 (en) | Recombinant tumor specific antibody and use thereof | |
DK1163271T3 (da) | Rekombinant IL-18 antistoffer og deres anvendelse | |
NO20034396L (no) | Rekombinante antistoff uttrykt sammen med GnTIII | |
NO20033418D0 (no) | Immunregulatoriske antistoffer og anvendelse derav | |
DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
DK1711207T3 (da) | Interferon-alpha-antistoffer og anvendelse heraf | |
DK1746375T3 (da) | Oxygendrevet forbrændingssystem og anvendelser deraf | |
NO20033387D0 (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
NO20033456L (no) | Modifiserte og stabiliserte GDF-propeptider og anvendelse derav | |
DE60124863D1 (de) | Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper | |
DK2662390T3 (da) | Interferon alpha receptor 1-antistoffer og anvendelse heraf | |
AU2002244968A1 (en) | Anti-osteopontin antibody and use thereof | |
DK1411064T3 (da) | Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer | |
NO20034159L (no) | Östrogen-gestagen-kombinasjonspreparat og anvendelse derav | |
DE50202730D1 (de) | Substituierte isoindole und ihre verwendung | |
EP1589033A4 (fr) | Anticorps et utilisation de ce dernier | |
DE60205008D1 (de) | Kettelverfahren und -vorrichtung | |
DE60219418D1 (de) | Silanylphenole und -naphthole | |
EP1437367A4 (fr) | Anticorps et son utilisation | |
IS8914A (is) | Mótefni sem blokka prótínið Cripto og notkun þeirra |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |